Genmab price target raised to $46 from $45 at Truist

Truist raised the firm’s price target on Genmab (GMAB) to $46 from $45 and keeps a Buy rating on the shares. The firm notes that signals are pointing to a more attractive revenue outlook for Genmab in 2025, driven largely by Darzalex and, to a lesser extent, Epkinly and Kesimpta, the analyst tells investors in a research note. The stock’s current valuation does little justice to Genmab’s established revenue streams, let alone the pipeline, Truist added.